arrow
P

Peter Libby

brigham and women s hospital
H指数:227
被引数:22.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cardiovascular risk, evaluation and management in patients with hypertriglyceridaemia: a Consensus Statement from the International Atherosclerosis Society

心血管风险、评估和管理在高三酰甘油血症患者中的共识声明:国际动脉粥样硬化学会

2026-11-120
PRE
Machine learning–driven spleen imaging and genomics uncover a splenic connection to coronary artery disease

机器学习驱动的脾脏成像和基因组学揭示脾脏与冠状动脉疾病之间的联系

2026-09-090
PRE
Immunological risk identified by single-cell multi-omics and cardiovascular outcomes

单细胞多组学鉴定的免疫风险与心血管结局

2026-08-140
OAAI
A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials

一种用于估算接受白细胞介素-6配体抑制剂ziltivekimab治疗的患者中游离白细胞介素-6的定量方法:与C反应蛋白的比较及其对ZEUS、HERMES和ARTEMIS心血管结局试验的启示

2026-05-280
PRE
Author Correction: The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis

作者更正:AIM2炎性小体在克隆性造血中加剧动脉粥样硬化

Nature
IF48.5
2026-05-140
PRE
Preemptive cardioprotection with a small molecule in rodents that suppresses genes predictive of heart failure

使用能抑制心力衰竭预测基因的小分子对啮齿动物进行预存性心脏保护

2026-05-130
OA
CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum

CVOT峰会报告2025:心血管-肾脏-代谢疾病连续谱上的进展

2026-05-060
OAAI
C-reactive protein and cardiovascular risk in the general population

C-反应蛋白和普通人群中的心血管风险

2025-12-011
PRE
The effects of interleukin-6-receptor inhibition on monocytes in STEMI: a substudy of the ASSAIL-MI trial

白细胞介素-6-受体抑制对STEMI中单核细胞的影响:ASSAIL-MI试验的亚组研究

2025-10-110
OAAI